Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 301–400 of 1,000
Acetylation of Sirt2 by p300 attenuates its deacetylase activity
Han, Y., Jin, Y.-H., Kim, Y.-J., Kang, B. Y., Choi, H.-J., Kim, D., Yeo, C., & Lee, K.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.042 · Cited by 108
Aggregation of Expanded Polyglutamine Domain in Yeast Leads to Defects in Endocytosis
Meriin, A. B., Zhang, X., Miliaras, N. B., Kazantsev, A., Chernoff, Y. O., McCaffery, J. M., Wendland, B., & Sherman, M. Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7554-7565.2003 · Cited by 107
“It was also found that formation of IBs often correlates with inhibition of several transcription programs, probably due to abnormal association of certain transcription factors with IBs (32, 45, 46).”
BackgroundInfluentialSelf-citationHDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
Effect of a short CAG (glutamine) repeat on human androgen receptor function
Ding, D., Xu, L., Menon, M., Reddy, G. P. V., & Barrack, E. R. (2003) · The Prostate · doi:10.1002/pros.10316 · Cited by 99
Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias
Matilla‐Dueñas, A., Sánchez, I., Corral‐Juan, M., Dávalos, A., Álvarez, R., & Latorre, P. (2009) · The Cerebellum · doi:10.1007/s12311-009-0144-2 · Cited by 115
“This is leading to new therapeutic strategies with HDAC inhibitors to treat neurodegeneration [61–63].”
BackgroundChen, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddh005 · Cited by 98
CRE-Mediated Transcription Is Increased in Huntington's Disease Transgenic Mice
Obrietan, K., & Hoyt, K. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3493-03.2004 · Cited by 98
“In particular, inhibition of cAMP response element (CRE)-mediated gene transcription has been hypothesized to contribute to HD pathology (Kazantsev et al., 1999; McCampbell et al., 2000, 2001; Shimohata et al., 2000; Steffan et al.,”
BackgroundKirilly, D., Wong, J. J. L., Lim, E. K. H., Wang, Y., Zhang, H., Wang, C., Liao, Q., Wang, H., Liou, Y., Wang, H., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.003 · Cited by 104
“, 2010) and polyglutamine expansion diseases (Steffan et al., 2001).”
InfluentialGiorgini, F., Möller, T., Kwan, W., Zwilling, D., Wacker, J. L., Hong, S., Tsai, L.-C. L., Cheah, C. S., Schwarcz, R., Guidetti, P., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708192200 · Cited by 97
The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons
Poletti, A. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.03.001 · Cited by 105
Runne, H., Régulier, E., Kuhn, A., Zala, D., Gokce, O., Perrin, V., Sick, B., Aebischer, P., Déglon, N., & Luthi-Carter, R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3044-08.2008 · Cited by 96
“…of soluble DNA-binding transcription factors (Dunah et al., 2002; Zuccato et al., 2003), abnormalities of chromatin biochemistry and organization (Steffan et al., 2001; Helmlinger et al., 2006; Ryu et al., 2006; Stack et al., 2007), and aggregate-driven nuclear transcription factor…”
BackgroundZhang, S., Feany, M. B., Saraswati, S., Littleton, J. T., & Perrimon, N. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.000653 · Cited by 96
“The HD-Q93 flies also develop a progressive degeneration of both the brain and other neuronal tissues, most prominently in the photoreceptor cells in the eye (Steffan et al., 2001).”
BackgroundMethodInfluentialCao, W., Song, H.-J., Gangi, T., Kelkar, A., Antani, I., Garza, D., & Konsolaki, M. (2008) · Genetics · doi:10.1534/genetics.107.078394 · Cited by 96
Genome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease
McFarland, K. N., Das, S., Sun, T. T., Leyfer, D., Xia, E., Sangrey, G. R., Kuhn, A., Luthi-Carter, R., Clark, T. W., Sadri-Vakili, G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041423 · Cited by 94
“behavioral phenotypes in animal models for a number of neurodegenerative diseases including HD [6,29–34], Parkinson’s disease [35], spinal and bulbar muscular atrophy [36], Alzheimer’s disease [37,38], dentatorubral-pallidoluysian atrophy [39], amyotrophic lateral sclerosis [40,41] and Friedreich’s ataxia [42].”
Zhang, X., Wharton, W., Yuan, Z., Tsai, S.-C., Olashaw, N., & Seto, E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5106-5118.2004 · Cited by 95
“Additionally, drugs that target HDACs may potentially be used against malaria and toxoplasmosis and for the treatment of Huntington’s disease (6, 52).”
BackgroundCloutier, P., & Coulombe, B. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.02.010 · Cited by 110
D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease
Lim, S., Chesser, A. S., Grima, J. C., Rappold, P. M., Blum, D., Przedborski, S., & Tieu, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024620 · Cited by 94
“The expanded glutamine stretch in mhtt has been shown to bind to either the polyQ domain of CBP and sequester it in nuclear inclusions [35–37] or bind to the acetyltransferase domain (outside the polyQ domain) in CBP [18,38], leading to the inhibiton of the HAT activity of CBP and ultimately, global histone deacetylat…”
InfluentialLiévens, J.-C., Rival, T., Iché, M., Chneiweiss, H., & Birman, S. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi067 · Cited by 94
“Using the UAS‐GAL4 bipartite system (34), we expressed selectively the polyQcontaining domain of human Htt (Httex1p) or an expanded polyQ alone ( 13 ) in the dEAAT1-expressing glial cells.”
MethodInfluentialLessing, D., & Bonini, N. M. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060029 · Cited by 104
“UAS-Htt-ex1Q93 [24] was a gift from Larry Marsh, Leslie Thompson (University of California Irvine), and Larry Goldstein (University of California San Diego), and is termed Htt174(Q93) in Figure S1; UAS-HttQ128 [25] was a gift of Troy Littleton (MIT), and is termed Htt676(Q128).”
BackgroundZádori, D., Geisz, A., Vámos, E., Vécsei, L., & Klivènyi, P. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.001 · Cited by 97
“The inhibition of HDACs might be able to restore the altered balance described above, as the application of such substances was found to arrest the polyglutamine-dependent neurodegeneration in different models of polyglutamine disease (Steffan et al., 2001; Gárdián et al., 2005).”
Fly models of Huntington's disease
Marsh, J. L., Pallos, J., & Thompson, L. M. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg271 · Cited by 114
“The possibility that sequestration and direct inhibition of AT protein activities might be contributing to pathogenesis in vivo was tested in Drosophila and other models by inhibiting the counteracting activity of H istone D e AC etylases (HDACs) both genetically and pharmacologically (39,42,51,52).”
MethodSelf-citationOf Flies and Man:Drosophila as a Model for Human Complex Traits
Mackay, T. F. C., & Anholt, R. R. H. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.7.080505.115758 · Cited by 92
“Inhibitors of histone deacetylase, including sodium butyrate and suberoylanilide hydroxamic acid administered as fly food supplements, substantially reduced the neurodegeneration of rhabdomeres in transgenic flies that express polyQ-Htt (165).”
BackgroundPathways to Biomedical Discovery
Thagard, P. R. (2003) · Philosophy of Science · doi:10.1086/375465 · Cited by 95
“For example, there is recent excitement concerning the prospect of treating Huntington’s disease, not by replacing the mutant gene that causes it, but by counteracting the effect of the defective protein that the gene produces (Steffan et al. 2001).”
BackgroundEnzymatic Catalysis: The Emerging Role of Conceptual Density Functional Theory
Roos, G., Geerlings, P., & Messens, J. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9034584 · Cited by 95
Zuccato, C., & Cattaneo, E. F. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_14 · Cited by 100
“A finding by Joan Steffan and Leslie Thompson at the University of California Irvine indicates that mutant huntingtin can interact with both the glutamine-rich activation domain and the acetyl transferase domain of CBP (Steffan et al. 2001).”
BackgroundChen, C. (2011) · PubMed · Cited by 101
Drosophila melanogaster as a model system for human brain cancers
Read, R. D. (2011) · Glia · doi:10.1002/glia.21148 · Cited by 96
“In recent years, specific Drosophila models have been created for several human diseases, including cancers and neurological disorders, and these models have produced observations about human disease that have been validated in mammalian systems (Choi et al., 2011; McBride et al., 2005; Read et al., 2005; Steffan et a…”
BackgroundLatouche, M., Lasbleiz, C., Martin, E., Monnier, V., Debeir, T., Prigent, A., Muriel, M., Morel, L. J., Ruberg, M., Brice, A., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5453-06.2007 · Cited by 105
Young, J. E., Gouw, L. G., Propp, S. S., Sopher, B. L., Taylor, J., Lin, A., Hermel, E., Logvinova, A. V., Chen, S. F., Chen, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705265200 · Cited by 103
From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease
Shulman, J. M., Shulman, L. M., Weiner, W. J., & Feany, M. Β. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084220.82329.60 · Cited by 106
Nucifora, F. C., Ellerby, L. M., Wellington, C. L., Wood, J. D., Herring, W. J., Sawa, A., Hayden, M. R., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211224200 · Cited by 90
Quinti, L., Casale, M., Moniot, S., Pais, T. F., Kanegan, M. J. V., Kaltenbach, L. S., Pallos, J., Lim, R. G., Naidu, S. D., Runne, H., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.05.015 · Cited by 92
“In this model, degeneration of photoreceptor neurons is visually scored by the presence of sur- viving rhabdomeres in the eyes of Drosophila expressing mHTTex1 (Steffan et al., 2001).”
BackgroundSelf-citationQiu, X., Xiao, X., Li, N., & Li, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.002 · Cited by 96
“…Crump et al. (2008) Bladder cancer Human Down-regulation of c-Myc Kelly et al. (2003) Breast cancer Human Up-regulation of p21 Luu et al. (2008) and Strobl et al. (2010) Phenylbutyrate Leukemia Human Down-regulation of c-Myc Warrell et al. (1998) Benzamide (MS-275) Leukemia Human Down-regulation…”
Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
Hogarth, P., Lovrecic, L., & Krainc, D. (2007) · Movement Disorders · doi:10.1002/mds.21632 · Cited by 89
“M, 41 yr 10 12 Nausea (1); headache (1) No F, 34 yr 10 12 Headache (1); gait instability (2) No M, 24 yr 10 12 Gait instability (1); increased depression (2) No F, 38 yr 13 15 Nausea (1) No M, 41 yr 11 15 Gait instability (1); vasovagal syncope w/blood draw (2) No M, 61 yr 5 15 No M, 42 yr 8 15 Nausea (1); diarrhea (1…”
BackgroundAbnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress
Woulfe, J. M. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00819.x · Cited by 88
Barbaro, B. A., Lukácsovich, T., Agrawal, N., Burke, J., Bornemann, D. J., Purcell, J. M., Worthge, S. A., Caricasole, A., Weiss, A., Song, W., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu504 · Cited by 95
Self-citationTrushina, E., Heldebrant, M. P., Perez-Terzic, C. M., Bortolon, R., Kovtun, I. V., Badger, J. D., Terzic, A., Estévez, A., Windebank, A. J., Dyer, R. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034961100 · Cited by 88
The Fly as a Model for Neurodegenerative Diseases: Is It Worth the Jump?
Cauchi, R. J., & van den Heuvel, M. (2006) · Neurodegenerative Diseases · doi:10.1159/000097303 · Cited by 88
Genetic and epigenetic defects in mental retardation
Kramer, J. M., & van Bokhoven, H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.009 · Cited by 104
Pathogenesis, animal models and therapeutics in Spinal and bulbar muscular atrophy (SBMA)
Katsuno, M., Adachi, H., Waza, M., Banno, H., Suzuki, K., Tanaka, F., Doyu, M., & Sobue, G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.021 · Cited by 95
Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease
Lee, J.-H., Hwang, Y. J., Kim, K. Y., Kowall, N. W., & Ryu, H. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0206-5 · Cited by 94
“Suberoyl bis-hydroxamic acid (SAHA) Class I and II HDACs (predominantly class I)/ inhibition htt ex1p polyQ expanded flies Inhibited neurodegeneration and impaired transport restoration [57]”
Polyglutamine diseases: a transcription disorder?
Okazawa, H. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3013-z · Cited by 98
Back to the future: the 'old-fashioned' way to new medications for neurodegeneration
Lansbury, P. T. (2004) · Nature Medicine · doi:10.1038/nrn1435 · Cited by 92
Baba, R., Hori, Y., Mizukami, S., & Kikuchi, K. (2012) · Journal of the American Chemical Society · doi:10.1021/ja306045j · Cited by 88
A Glutamine-Rich Trail Leads to Transcription Factors
Freiman, R. N., & Tjian, R. (2002) · Science · doi:10.1126/science.1073845 · Cited by 87
Kumar, A., Vaish, M., & Ratan, R. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.016 · Cited by 82
Disrupted Transforming Growth Factor-β Signaling in Spinal and Bulbar Muscular Atrophy
Katsuno, M., Adachi, H., Minamiyama, M., Waza, M., Doi, H., Kondo, N., Mizoguchi, H., Nitta, A., Yamada, K., Banno, H., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0388-10.2010 · Cited by 85
“P/CAF also interacts with an N-terminal fragment of huntingtin that contains an expanded polyglutamine tract (Steffan et al., 2001).”
BackgroundPuerta, E., Hervías, I., Barros-Miñones, L., Jordán, J., Ricobaraza, A., Cuadrado‐Tejedor, M., García‐Osta, A., & Aguirre, N. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.013 · Cited by 88
“…latter mechanism, the cAMP response element-binding protein (CREB) transcriptional pathway is impaired by mutated huntingtin what has been hypothesized to play a critical role in HD pathology (Steffan et al., 2000; Nucifora et al., 2001; Steffan et al., 2001; Jiang et al., 2003; Choi et al., 2009).”
BackgroundThe role of short-chain fatty acids in central nervous system diseases
Dong, Y., & Cui, C. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04471-8 · Cited by 89
“Butyrate could reverse transcriptional inhibition, reduce neuronal apoptosis by increasing the histone acetylation level in these diseases [35–37, 73, 74], eventually delayed the occurrence of motor injury and prolonged the life span of mice [35, 37].”
BackgroundCEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice
Apostol, B. L., Simmons, D. A., Zuccato, C., Illes, K., Pallos, J., Casale, M., Conforti, P., Ramos, C., Roarke, M., Kathuria, S., et al. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.04.007 · Cited by 83
“Flies were transferred to fresh food every day, and assayed for neurodegeneration immediately after eclosion (day0) and at day 7 post-eclosion, using the pseudopupil technique (Marsh et al., 2000; Steffan et al., 2001).”
MethodSelf-citationParkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids
Yang, X., Ai, P., He, X., Mo, C., Zhang, Y., Xu, S., Lai, Y., Qian, Y., & Xiao, Q. (2022) · Movement Disorders · doi:10.1002/mds.29063 · Cited by 82
Ambegaokar, S. S., Roy, B., & Jackson, G. R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.026 · Cited by 90
Self-citationBax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation
Li, Y., Yokota, T., Gama, V., Yoshida, T., Gómez, J. A., Ishikawa, K., Sasaguri, H., Cohen, H. Y., Sinclair, D. A., Mizusawa, H., et al. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402219 · Cited by 95
“CBP) from chromosomes.(2,3) The subsequent suppression of histone acetylation decreases cellular transcriptional activities, and these changes are implicated to cause polyQ toxicity.”
BackgroundDendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease
Richards, P., Didszun, C., Campesan, S., Simpson, A., Horley, B., Young, K. W., Glynn, P., Cain, K., Kyriacou, C. P., Giorgini, F., et al. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.127 · Cited by 82
“Previous studies determined that B20–30% of flies expressing HttQ93 emerge from the pupal case.(39,40) Similarly, in our experiments, we observed that B40% of HD flies emerged as adults (Figure 5c).”
Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy
Menzies, F. M., Hourez, R., Imarisio, S., Raspe, M., Sadiq, O., Chandraratna, D., O'Kane, C., Rock, K. L., Reits, E., Goldberg, A. L., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq385 · Cited by 82
Mérienne, K., Helmlinger, D., Perkin, G. R., Devys, D., & Trottier, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212049200 · Cited by 90
The spinocerebellar ataxias: Order emerges from chaos
Margolis, R. L. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0072-8 · Cited by 90
Histone deacetylases: Focus on the nervous system
Morrison, B. E., Majdzadeh, N., & D’Mello, S. R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7035-9 · Cited by 95
Epigenetic programming of neurodegenerative diseases by an adverse environment
Babenko, O., Kovalchuk, I., & Metz, G. A. S. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.038 · Cited by 83
Axon injury and stress trigger a microtubule-based neuroprotective pathway
Chen, L., Stone, M. C., Tao, J., & Rolls, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121180109 · Cited by 80
Tanaka, M., Machida, Y., & Nukina, N. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0632-2 · Cited by 87
Holbert, S., Dedeoglu, A., Humbert, S., Saudou, F., Ferrante, R. J., & Néri, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437967100 · Cited by 80
Huntingtin Aggregation Kinetics and Their Pathological Role in aDrosophilaHuntington’s Disease Model
Weiss, K. R., Kimura, Y., Lee, W.-C. M., & Littleton, J. T. (2011) · Genetics · doi:10.1534/genetics.111.133710 · Cited by 85
“1999) and Huntington’s disease (GUNAWARDENA et al. 2003; JACKSON et al. 1998; LEE et al. 2004; STEFFAN et al. 2001).”
Recent Applications of Diazirines in Chemical Proteomics
Halloran, M. W., & Lumb, J. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201805004 · Cited by 84
Biologically active molecules that reduce polyglutamine aggregation and toxicity
Desai, U. A., Pallos, J., Ma, A. A. K., Stockwell, B. R., Thompson, L. M., Marsh, J. L., & Diamond, M. I. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl135 · Cited by 79
“The number of rhabdomeres in treated versus untreated flies was analyzed 7 days post-eclosion by the pseudopupil technique as described ( 26 ,47).”
BackgroundMethodInfluentialSelf-citationHistone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Mai, A., Rotili, D., Valente, S., & Kazantsev, A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649349 · Cited by 78
Self-citationDoes Huntingtin play a role in selective macroautophagy?
Steffan, J. S. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12718 · Cited by 89
Self-citationJin, Y. N., & Johnson, G. V. W. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9286-7 · Cited by 77
“2000), leading to an increase in mHtt-induced cytotoxicity (Steffan et al. 2001).”
BackgroundYang, C., Rahimpour, S., Lu, J., Pacak, K., Ikejiri, B., Brady, R. O., & Zhuang, Z. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221046110 · Cited by 77
Multiple Aspects of Gene Dysregulation in Huntington’s Disease
Moumné, L., Betuing, S., & Caboche, J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00127 · Cited by 77
“By interacting with CBP and p300/CBP-associated factor (P/CAF), Exp-Htt blocks their intrinsic HAT activity (29, 30, 63, 64).”
BackgroundDrug-Induced Epigenetic Changes Produce Drug Tolerance
Wang, Y., Krishnan, H. R., Ghezzi, A., Yin, J. C. P., & Atkinson, N. S. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050265 · Cited by 81
“Moreover, the administration of HDAC inhibitors has been shown to enhance long-term memory, arrest neurodegeneration, and alter cocaine responses [11,12,17,18].”
BackgroundPharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders
Gupta, R., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117278 · Cited by 74
Epigenetic mechanisms of neurodegenerative diseases and acute brain injury
Bertogliat, M. J., Morris-Blanco, K. C., & Vemuganti, R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104642 · Cited by 87
Slepko, N., Bhattacharyya, A. M., Jackson, G. R., Steffan, J. S., Marsh, J., Thompson, L. M., & Wetzel, R. B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602348103 · Cited by 78
Self-citationBai, G., Cheung, I., Shulha, H. P., Coelho, J. E., Li, P., Dong, X., Jakovcevski, M., Wang, Y., Grigorenko, A., Jiang, Y., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu561 · Cited by 77
Surviving Blood Loss Without Fluid Resuscitation
Shults, C., Sailhamer, E. A., Li, Y., Liu, B., Tabbara, M., Butt, M., Shuja, F., DeMoya, M. A., Velmahos, G. C., & Alam, H. B. (2008) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181650ff3 · Cited by 75
Huntington?s disease: pathomechanism and therapeutic perspectives
G�rdi�n, G., & V�csei, L. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0201-4 · Cited by 83
“A number of HDAC inhibitors reduce cell loss both in vitro and in Drosophila and mouse models of HD, suggesting that histone acetylation is the cause of cell death (McCampbell et al., 2001; Steffan et al., 2001).”
InfluentialNaia, L., Carmo, C., Campesan, S., Fão, L., Cotton, V. E., Valero, J., Lopes, C., Rosenstock, T. R., Giorgini, F., & Rego, A. C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.031 · Cited by 75
Emerging approaches for histone deacetylase inhibitor drug discovery
Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 82
Teschendorf, D., & Link, C. D. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-38 · Cited by 75
“Inhibition of histone deacetylase activity can counter this effect and subsequently reduce Ht-polyQ toxicity [8,9].”
BackgroundSteinert, J. R., Campesan, S., Richards, P., Kyriacou, C. P., Forsythe, I. D., & Giorgini, F. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds117 · Cited by 76
Sleiman, S. F., Basso, M., Mahishi, L., Kozikowski, A. P., Donohoe, M. E., Langley, B., & Ratan, R. R. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902810345 · Cited by 74
“reasoned that HDAC inhibition should alleviate this defect in cellular HAT activity and prevent cell loss [24].”
Safety and efficacy of valproic acid treatment in SCA3/MJD patients
Lei, L., Yang, G., Wang, J., Chuang, D., Song, W., Tang, B., & Jiang, H. F. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.03.005 · Cited by 78
Giampà, C., Patassini, S., Borreca, A., Laurenti, D., Marullo, F., Bernardi, G., Menniti, F. S., & Fusco, F. R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.014 · Cited by 80
“Reduced CREBregulated transcription has been hypothesized to contribute to HD pathology (Jiang et al., 2003, Kazantsev et al., 1999, Nucifora et al., 2001, Shimohata et al., 2000, Steffan et al., 2000, 2001).”
BackgroundAtrophin Proteins: An Overview of a New Class of Nuclear Receptor Corepressors
Wang, L., & Tsai, C.-C. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06009 · Cited by 72
“…HDAC inhibitors [Marks et al., 2001] have been tested as promising agents in treating blood-borne cancers, and also in treating polyglutamine diseases [Carey and La Thangue, 2006; Hockly et al., 2003; McCampbell et al., 2001; Minamiyama et al., 2004; Steffan et al., 2001;Ying et al., 2006].”
Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors
Futter, M., Diekmann, H., Schoenmakers, E., Sadiq, O., Chatterjee, K., & Rubinsztein, D. C. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066399 · Cited by 73
Fluorescent Probes for Single-Step Detection and Proteomic Profiling of Histone Deacetylases
Xie, Y., Ge, J., Lei, J. H., Peng, B., Zhang, H., Wang, D., Pan, S., Chen, G., Chen, L., Wang, Y., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b07334 · Cited by 76
Iijima-Ando, K., Zhao, L., Gatt, A., Shenton, C., & Iijima, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq068 · Cited by 72
Role of Heat Shock Proteins During Polyglutamine Neurodegeneration: Mechanisms and Hypothesis
Wyttenbach, A. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:069 · Cited by 79
Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1
Hong, W., Kim, A. Y., Ky, S., Rakowski, C., Seo, S.-B., Chakravarti, D., Atchison, M., & Blobel, G. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3729-3743.2002 · Cited by 74
“deacetylation in cellular functions in diverse tissues (73).”
BackgroundIndividual histone deacetylases in Drosophila modulate transcription of distinct genes
Cho, Y., Griswold, A., Campbell, C., & Min, K.-T. (2005) · Genomics · doi:10.1016/j.ygeno.2005.07.007 · Cited by 71
Epigenetic Regulation of Spinal CXCR2 Signaling in Incisional Hypersensitivity in Mice
Sun, Y., Sahbaie, P., Liang, D., Li, W., Li, X., Shi, X., & Clark, J. D. (2013) · Anesthesiology · doi:10.1097/aln.0b013e31829ce340 · Cited by 73
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
“In vivo experiments have revealed that the ectopic overexpression of mutant human HTT (exon 1 with expanded CAG repeats) in the neural tissue of transgenic flies causes neurodegeneration (12, 13).”
BackgroundUpdate on Huntington's disease: Advances in care and emerging therapeutic options
Zielonka, D., Mielcarek, M., & Landwehrmeyer, G. B. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.013 · Cited by 86
Milestones in Huntington disease
Shoulson, I., & Young, A. B. (2011) · Movement Disorders · doi:10.1002/mds.23685 · Cited by 70
“Potential disease-modifying treatments might best be initiated prior to the onset of HD, when pathogenic mechanisms are potentially more reversible.(81) A randomized, controlled study (PREQUEL) has been designed to examine the safety, tolerability, and dosage of coenzyme Q10 in unaffected (premanifest) individuals who…”
BackgroundLithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway
Berger, Z., Ttofi, E. K., Michel, C. H., Pasco, M. Y., Tenant, S., Rubinsztein, D. C., & O'Kane, C. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi331 · Cited by 70
“Thus, we have supported our findings in various models and using different read-outs, which represent a more rigorous approach than often previously reported (8,11, 12 ).”
ResultSuppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1
Kazemi‐Esfarjani, P., & Benzer, S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.21.2657 · Cited by 78
The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration
Leegwater‐Kim, J., & Cha, J.-H. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.128 · Cited by 70
Big ideas for small brains: what can psychiatry learn from worms, flies, bees and fish?
Burne, T. H. J., Scott, E. K., van Swinderen, B., Hilliard, M. A., Reinhard, J., Claudianos, C., Eyles, D. W., & McGrath, J. J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.35 · Cited by 82
Yi, J., Zhang, L., Tang, B., WeiWei, H., Zhou, Y., Chen, Z., Jia, D., & Jiang, H. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054792 · Cited by 69
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.